Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,81 HKD | -.--% | +1,25% | -4,71% |
23/05 | Inari Medical klaagt Imperative Care, Truvic Medical aan wegens vermeende patentinbreuk | MT |
23/05 | Inari Medical klaagt Imperative Care, Truvic Medical aan wegens vermeende octrooi-inbreuk | MT |
Omzet 2022 | 279 mln. 35,7 mln. 32,93 mln. | Omzet 2023 | 305 mln. 38,97 mln. 35,94 mln. | Marktkapitalisatie | 2,53 mld. 323 mln. 298 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -81 mln. -10,36 mln. -9,55 mln. | Nettowinst (verlies) 2023 | -206 mln. -26,35 mln. -24,3 mln. | EV/omzet 2022 | 14,6 x |
Nettoschuld 2022 | 1,43 mld. 183 mln. 169 mln. | Nettoschuld 2023 | 1,4 mld. 179 mln. 165 mln. | EV/omzet 2023 | 12,9 x |
K/w-verhouding 2022 |
-32,6
x | K/w-verhouding 2023 |
-12,3
x | Werknemers | 205 |
Dividendrendement 2022 |
0,56% | Dividendrendement 2023 |
0,59% | Vrij verhandelbaar | 36,78% |
1 week | +1,25% | ||
1 maand | +2,53% | ||
3 maanden | +1,25% | ||
6 maanden | -4,71% | ||
Lopend jaar | -4,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Tun Nei Cheng
CEO | Chief Executive Officer | 60 | 15-12-14 |
Kar Lee Chan
BRD | Director/Board Member | 68 | 02-01-14 |
Chun Lung Cheng
PRN | Corporate Officer/Principal | 24 | 01-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Yu Chun Chow
BRD | Director/Board Member | 76 | 15-12-14 |
Tun Nei Cheng
CEO | Chief Executive Officer | 60 | 15-12-14 |
Wang Kei Wah
BRD | Director/Board Member | 57 | 27-11-13 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
31-05-24 | 0,81 | -.--% | 270 000 |
30-05-24 | 0,81 | +1,25% | 340 000 |
29-05-24 | 0,8 | +1,27% | 360 000 |
28-05-24 | 0,79 | -2,47% | 190 000 |
27-05-24 | 0,81 | +1,25% | 90 000 |
uitgestelde koers Hong Kong S.E., 31 mei 2024 om 10:08 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-4,71% | 308 mln. | |
+10,47% | 147 mld. | |
+14,92% | 78,44 mld. | |
+0,99% | 46,86 mld. | |
-20,50% | 42,17 mld. | |
+5,08% | 28,38 mld. | |
+23,43% | 15,15 mld. | |
+15,03% | 14,31 mld. | |
+38,50% | 10,82 mld. | |
+18,15% | 9,99 mld. |